Kawasaki Disease Clinical Trial
Official title:
Measurement of Antibodies in Adults With a History of Kawasaki Disease
Kawasaki disease (KD) is an acute systemic vasculitic syndrome with coronary tropism. It has
been reported worldwide, but it is ten times more common in Asian population. It is the
second vasculitis of the child by its frequency after rheumatoid purpura. It occurs in 80%
of cases between 1 and 5 years, with a maximal incidence around the age of 12 months.
KD is not well understood and the cause is yet unknown. It may be an autoimmune disorder.
The problem affects the mucous membranes, lymph nodes, walls of the blood vessels, and the
heart.The clinical picture of KD associate a persistent fever and an antipyretics resistance
with mucocutaneous signs and bulky cervical lymphadenopathy usually unilateral.
There is currently no vaccine available against Kawasaki disease so it is extremely
important to be able to recognize symptoms before they set in and become too severe.
Chagas disease (CD) is caused by the parasite Trypanosoma cruzi. Acute CD occurs immediately
after infection, may last up to a few weeks or months. Infection may be mild or
asymptomatic. There may be fever or swelling around the site of inoculation, and acute
infection may result in severe inflammation of the heart muscle. The notion that the
pathology of CD has an autoimmune component was initially based on the finding of
circulating antibodies binding heart tissue antigens in patients chronically infected with
T. cruzi.
A recent study reports a possible antigen (non-cruzi-related antibody NCRA) mimicry
characterized by a serological reactivity to a well-defined T. cruzi antigen in blood
samples from individuals not exposed to the parasite. The measured seroprevalence of such
cross-reactivity is in favor of a highly prevalent immunogen acquired in childhood.
There are similarities in mechanism of CD and KD: it could be interesting to explore the
presence of NCRA in blood samples from adults with a history of KD.
The objective of the study is the measurement of the biomarker NCRA in serum in adults with
a history of KD compare to a control population. This measurement and the prevalence may
permit to associate the NCRA to a possible pathogenic agent.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
| Recruiting |
NCT02951234 -
A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease
|
N/A | |
| Active, not recruiting |
NCT04747847 -
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
|
Early Phase 1 | |
| Withdrawn |
NCT04535518 -
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
|
Phase 3 | |
| Recruiting |
NCT01917721 -
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
|
Phase 2 | |
| Recruiting |
NCT04656184 -
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
|
Phase 3 | |
| Recruiting |
NCT03200561 -
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
|
Phase 3 | |
| Completed |
NCT01440075 -
Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease
|
N/A | |
| Completed |
NCT02179853 -
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02980263 -
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
|
Phase 2 | |
| Enrolling by invitation |
NCT02359643 -
Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease
|
N/A | |
| Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
| Completed |
NCT00760435 -
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
|
Phase 3 | |
| Completed |
NCT00841789 -
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05643651 -
Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease
|
Phase 4 | |
| Recruiting |
NCT02114099 -
Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05091229 -
A Blood Test to Diagnose Kawasaki Disease
|
||
| Completed |
NCT01431105 -
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Recruiting |
NCT06305611 -
European and North Indian Cohort of KaWasaki dIsease
|